Cargando…
Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of gluc...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350083/ https://www.ncbi.nlm.nih.gov/pubmed/32695525 http://dx.doi.org/10.1155/2020/7437892 |
_version_ | 1783557201708711936 |
---|---|
author | Sexe, Jordan Mayes, Chadwick Tofts, Peter |
author_facet | Sexe, Jordan Mayes, Chadwick Tofts, Peter |
author_sort | Sexe, Jordan |
collection | PubMed |
description | Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of glucose will mask hyperglycemia during DKA. This can lead to a delayed diagnosis of DKA and worsen outcomes. In this report, we detail a case of euglycemic DKA in a patient who presented to the Emergency Department meeting criteria for septic shock. |
format | Online Article Text |
id | pubmed-7350083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-73500832020-07-20 Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin Sexe, Jordan Mayes, Chadwick Tofts, Peter Case Rep Crit Care Case Report Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of glucose will mask hyperglycemia during DKA. This can lead to a delayed diagnosis of DKA and worsen outcomes. In this report, we detail a case of euglycemic DKA in a patient who presented to the Emergency Department meeting criteria for septic shock. Hindawi 2020-06-30 /pmc/articles/PMC7350083/ /pubmed/32695525 http://dx.doi.org/10.1155/2020/7437892 Text en Copyright © 2020 Jordan Sexe et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Sexe, Jordan Mayes, Chadwick Tofts, Peter Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin |
title | Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin |
title_full | Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin |
title_fullStr | Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin |
title_full_unstemmed | Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin |
title_short | Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin |
title_sort | euglycemic diabetic ketoacidosis in a lung cancer patient using empagliflozin |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350083/ https://www.ncbi.nlm.nih.gov/pubmed/32695525 http://dx.doi.org/10.1155/2020/7437892 |
work_keys_str_mv | AT sexejordan euglycemicdiabeticketoacidosisinalungcancerpatientusingempagliflozin AT mayeschadwick euglycemicdiabeticketoacidosisinalungcancerpatientusingempagliflozin AT toftspeter euglycemicdiabeticketoacidosisinalungcancerpatientusingempagliflozin |